GNNSF Stock Financial Analysis - Genscript Biotech Corporation (OTCPK) Stock

Overview

Genscript Biotech Corporation is a prominent biotechnology company based in Nanjing, China. It operates globally, providing comprehensive services and products in the bio-pharmaceutical industry. The company specializes in gene synthesis, pharmaceutical research, biologics development, and industrial synthetic biology applications. Genscript's notable projects include the development of plasmid and viral vector-based therapeutics and CRISPR-Cas9 gene editing technology services, which are pivotal in advanced therapies, including oncology treatments. Additionally, it has significantly contributed to the fight against COVID-19 through the development of diagnostic products and vaccine research at its bioresearch and manufacturing facilities. This work positions Genscript as an integral player in the biotechnology sector, fostering innovations that address critical medical needs.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Genscript Biotech Corporation as of June 30, 2025 is 828.10 MM.
The operating income for Genscript Biotech Corporation as of June 30, 2025 is 179.43 MM.
The net income for Genscript Biotech Corporation as of June 30, 2025 is 3,111.53 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	828.10	179.43	3,111.53
2025-03-31	711.29	94.35	3,036.70
2024-12-31	594.49	9.28	2,961.88
2024-06-30	1,009.59	-343.99	-177.01
2024-03-31	924.56	-379.89	-136.24
2023-12-31	560.48	26.19	-95.48
2023-09-30	773.47	-449.55	-140.20
2023-06-30	707.42	-483.31	-184.93
2023-03-31	666.56	-460.64	-205.89
2022-12-31	625.70	-437.98	-226.85
2022-09-30	597.91	-421.09	-314.97
2022-06-30	570.12	-404.20	-403.10
2022-03-31	530.11	-391.74	-380.90
2021-12-31	490.10	-379.29	-358.71
2021-09-30	482.54	-315.85	-265.42
2021-06-30	454.02	-272.17	-182.97
2021-03-31	422.43	-238.36	-193.96
2020-12-31	390.85	-204.55	-204.94
2020-09-30	354.36	-189.76	-193.80
2020-06-30
2020-03-31

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31	1.40	1.36
2024-06-30	-0.08	-0.08
2024-03-31	-0.06	-0.06
2023-12-31	-0.05	-0.05
2023-09-30	-0.07	-0.07
2023-06-30	-0.09	-0.09
2023-03-31	-0.10	-0.10
2022-12-31	-0.11	-0.11
2022-09-30	-0.15	-0.15
2022-06-30	-0.19	-0.19
2022-03-31	-0.18	-0.19
2021-12-31	-0.18	-0.18
2021-09-30	-0.13	-0.13
2021-06-30	-0.09	-0.09
2021-03-31	-0.10	-0.10
2020-12-31	-0.11	-0.11
2020-09-30	-0.10	-0.10
2020-06-30	-0.10	-0.10
2020-03-31	-0.08	-0.08

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Genscript Biotech Corporation as of June 30, 2025 is 228.41 MM.
The cash from investing activities for Genscript Biotech Corporation as of June 30, 2025 is -421.95 MM.
The cash from financing activities for Genscript Biotech Corporation as of June 30, 2025 is 87.36 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	228.41	-421.95	87.36
2025-03-31	152.03	-939.16	76.94
2024-12-31	75.65	-1,456.36	66.52
2024-06-30	-19.89	-1,036.24	53.81
2024-03-31	-153.40	-696.98	561.03
2023-12-31	-286.91	-357.73	1,068.26
2023-09-30	-266.19	-459.35	1,249.68
2023-06-30	-245.46	-560.97	1,431.11
2023-03-31	-182.88	-502.13	925.21
2022-12-31	-120.29	-443.30	419.32
2022-09-30	-141.61	-411.90	398.35
2022-06-30	-162.93	-380.50	377.38
2022-03-31	-149.86	-296.52	639.76
2021-12-31	-136.79	-212.55	902.14
2021-09-30	-127.30	-184.88	711.53
2021-06-30	-117.81	-157.21	520.93
2021-03-31	-134.45	-128.69	572.57
2020-12-31	-151.09	-100.17	624.20
2020-09-30	-48.44	-180.27	627.60
2020-06-30
2020-03-31

Valuation Metrics : PE, PriceToBook, PriceToTBV

The p/book for Genscript Biotech Corporation as of June 30, 2025 is 0.52.

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30		0.52
2025-03-31		0.52	0.52
2024-12-31		1.23	1.25
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31	-10.58	1.77	1.84
2020-12-31	-10.01	2.51	2.64
2020-09-30	-10.41	2.47	2.60
2020-06-30	-11.03	2.27	2.39
2020-03-31	-14.14	2.23	2.35

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

The ebit/ev for Genscript Biotech Corporation as of June 30, 2025 is -0.06.
The ebit (3y)/ev for Genscript Biotech Corporation as of June 30, 2025 is -0.11.

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30	-0.06	-0.11
2025-03-31	-0.06	-0.11
2024-12-31	-0.09	-0.11
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31	-0.22	-0.12
2020-12-31	-0.20	-0.09
2020-09-30	-0.19	-0.07
2020-06-30	-0.18	-0.06
2020-03-31	-0.14	-0.04

Management Effectiveness

The roa for Genscript Biotech Corporation as of June 30, 2025 is 0.89.
The roe for Genscript Biotech Corporation as of June 30, 2025 is 1.62.
The roic for Genscript Biotech Corporation as of June 30, 2025 is 0.59.
The croic for Genscript Biotech Corporation as of June 30, 2025 is -0.26.
The ocroic for Genscript Biotech Corporation as of June 30, 2025 is 0.01.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	0.89	1.62	0.59	-0.26	0.01
2025-03-31	0.89	1.62	0.59	-0.26	0.01
2024-12-31	-0.05	-0.09	-0.06	-0.35	-0.01
2024-06-30		-0.07
2024-03-31		-0.07
2023-12-31			-0.07	0.25
2023-09-30			-0.09	0.28
2023-06-30		-0.21
2023-03-31		-0.23
2022-12-31
2022-09-30		-0.28
2022-06-30		-0.33	-0.42
2022-03-31		0.00
2021-12-31		0.00
2021-09-30	-0.18	-0.33
2021-06-30	-0.13		-0.15	0.21	-0.10
2021-03-31	-0.13	-0.22	-0.16	0.26	-0.11
2020-12-31	-0.23	-0.55	-0.24	0.43	-0.17
2020-09-30	-0.22	-0.52	-0.22	0.46	-0.04
2020-06-30	-0.21	-0.40	-0.19	0.45	0.03
2020-03-31	-0.16	-0.30	-0.15	0.10	-0.00

Gross Margins

The gross margin for Genscript Biotech Corporation as of June 30, 2025 is 0.46.
The net margin for Genscript Biotech Corporation as of June 30, 2025 is 4.98.
The operating margin for Genscript Biotech Corporation as of June 30, 2025 is 0.02.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	0.46	4.98	0.02
2025-03-31	0.46	4.98	0.02
2024-12-31	0.54	-0.18	-0.34
2024-06-30
2024-03-31
2023-12-31
2023-09-30		-0.26	-0.68
2023-06-30		-0.26	-0.68
2023-03-31		-0.31	-0.69
2022-12-31
2022-09-30			0.00
2022-06-30		-0.66	0.00
2022-03-31
2021-12-31
2021-09-30
2021-06-30	0.63	-0.40	-0.60
2021-03-31	0.64	-0.46	-0.56
2020-12-31	0.65	-0.52	-0.52
2020-09-30	0.66	-0.55	-0.54
2020-06-30	0.66	-0.57	-0.55
2020-03-31	0.66	-0.47	-0.52

HK:1548	HK$17.36
DE:G51	€1.86